Co-Diagnostics Shares Soar 56% After Equity Raise and Lawsuit Dismissal

Introduction

Co-Diagnostics, Inc. (Nasdaq: CODX) is a Salt Lake City-based molecular diagnostics company founded in 2013. The firm develops, manufactures, and markets real-time PCR (polymerase chain reaction) diagnostic solutions for point-of-care, at-home, and research use. As of October 27, 2025, CODX shares traded at $0.5497, reflecting a 56.74% increase on a volume of 32,568,083 shares on the Nasdaq Capital Market.

Corporate Structure and Expertise

Headquartered in Utah, Co-Diagnostics employs between 51 and 200 people with expertise in molecular biology, assay design, and instrument engineering. The company's proprietary Co-Primers® technology underpins its Co-Dx PCR platform, which includes:

• Co-Dx Box: a portable qPCR cycler that requires no optical alignment or calibration
• Logix Smart®: real-time PCR tests for infectious diseases such as COVID-19, influenza, and tuberculosis
• Vector Smart®: multiplex assays for mosquito testing in public health and vector-control programs

Co-Diagnostics offers in-vitro diagnostic (IVD) products in multiple regions and provides research-use-only reagents for life-science applications.

Molecular diagnostics by CDC

Developments and News

On March 6, 2025, Co-Diagnostics announced that the U.S. District Court for the District of Utah granted summary judgment to dismiss a Section 10(b) securities class action (Gelt Trading, Ltd. v. Co-Diagnostics, Inc., Case No. 2:20-cv-00368). The lawsuit had challenged claims related to the performance metrics of the Logix Smart® COVID-19 test.

On January 14, 2025, CEO Dwight Egan participated in an interview on Nasdaq Listings hosted by Kristina Ayanian during the Silicon Slopes Summit, discussing the company's objectives for its point-of-care PCR platform. On February 4, 2025, Co-Diagnostics’ joint venture CoSara Diagnostics Pvt. Ltd. hosted a Holistic Cancer Awareness lecture series in India, which marked an extension of the firm’s activities into oncology screening.

Through a partnership with Arabian Eagle Manufacturing, Co-Diagnostics launched CoMira Diagnostics to localize production of the Co-Dx™ PCR platform in Saudi Arabia and the broader MENA region, aligned with Saudi Vision 2030 goals for health security and technology localization.

On October 20, 2025, Co-Diagnostics filed two SEC disclosures:

• Form 8-K (items 1.01, 1.02, 9.01), detailing operational updates and officer appointments.
• Form 424B5 Prospectus under an Equity Distribution Agreement with Maxim Group LLC to offer up to $4,086,645 of common stock, utilizing “at-the-market” mechanisms to support working capital, research and development, and expansion initiatives.

Financial and Strategic Analysis

CODX shares recorded a significant gain on October 27, 2025, following the October 20, 2025 equity filing. The proposed offering of up to $4.09 million represents approximately 14% of the company’s non-affiliate market capitalization, estimated at around $28.9 million as of the filing date. Management has indicated that net proceeds will be allocated toward instrument development, regulatory submissions, and expanded manufacturing capacity.

While Co-Diagnostics has reported limited profitability to date, it has generated recurring revenue from consumable sales and grants. The dismissal of the class action on March 6, 2025, could alleviate uncertainty among investors. The joint venture in Saudi Arabia and ongoing product registrations in Europe and Asia may position Co-Diagnostics for potential growth in decentralized testing.

Market Position and Industry Context

The global molecular diagnostics market is driven by the demand for rapid and accurate infectious disease detection outside of central laboratories. Real-time PCR is regarded as the standard for sensitivity and specificity. Co-Diagnostics has sold over 34 million real-time PCR tests to date, competing with established companies by providing lower instrument costs, portability, and cloud-enabled result management. Its focus on both human health and vector control provides a distinct advantage in emerging markets and public health initiatives.

tl;dr

On October 20, 2025, Co-Diagnostics filed an equity prospectus to raise up to $4.09 million through “at-the-market” share sales via Maxim Group. The company’s stock increased by 56.74% to $0.5497 on October 27, 2025, in light of the capital raise and the dismissal of a class-action lawsuit regarding COVID-19 test performance on March 6, 2025. Strategic activities include the CEO's interview at the Silicon Slopes Summit on January 14, 2025, the CoSara Diagnostics cancer awareness initiative in India on February 4, 2025, and the establishment of CoMira Diagnostics in Saudi Arabia. Future plans include utilizing proceeds for research and development, regulatory approvals, and expanding point-of-care installations globally.